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Abstract
Background
Cancer stem cells represent a population of immature tumor cells found in most solid tu-
mors. Their peculiar features make them ideal models for studying drug resistance and sen-
sitivity. In this study, we investigated whether cancer stem cells isolation and in vitro
sensitivity assay are feasible in a clinical setting.
Methods
Cancer stem cells were isolated from effusions or fresh cancer tissue of 23 patients who
progressed after standard therapy failure. Specific culture conditions selected for immature
tumor cells that express markers of stemness. These cells were exposed in vitro to chemo-
therapeutic and targeted agents.
Results
Cancer stem cells were extracted from liver metastases in 6 cases (25%), lung nodules in 2
(8%), lymph node metastases in 3 (12.5%) and pleural/peritoneal/pericardial effusion in 13
(54%). Cancer stem cells were successfully isolated in 15 patients (63%), including 14 with
lung cancer (93.3%). A sensitivity assay was successfully performed in 7 patients (30.4%),
with a median of 15 drugs/combinations tested (range 5-28) and a median time required for
results of 51 days (range 37-95).
Conclusion
The approach used for the STELLA trial allowed isolation of cancer stem cells in a consis-
tent proportion of patients. The low percentage of cases completing the full procedure and
the long median time for obtaining results highlights the need for a more efficient procedure.
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Introduction
Cancer is the second cause of death after cardiovascular diseases worldwide and lung, breast,
and colorectal tumors are the three major players. Breast (BC) and lung cancer (LC) are the
leading cause of cancer death in women and men, respectively, while colorectal cancer (CRC)
accounts for approximately 10% of all cancer incidence and mortality [1]. Surgical resection
and adjuvant therapy can cure early stage primary tumors. On the other hand, metastatic dis-
ease is mostly incurable because of its systemic nature and resistance to therapeutic agents. In-
deed, more than 90% of cancer-related deaths can be ascribed to recurrence/relapse and not to
primary lesions [2,3]. In the last two decades, treatment outcome has notably improved thanks
to a better understanding of cancer biology, the introduction of novel targeted/chemotherapeu-
tic agents and, most importantly, the selection of patients based on biomarkers or tumor-based
assays. However, even this novel approach proved to be unsuitable to cure patients with meta-
static disease [4–7]. This clinical reality underscores the need to evaluate novel approaches for
the treatment of cancer patients and to develop new clinical tools for the selection of the best
treatment option for the individual patient.
In recent years, a small subpopulation of undifferentiated cancer cells with stem-like fea-
tures was identified within tumors and named cancer stem cells (CSC) or tumor initiating cells.
They seem responsible for cancer initiation, sustenance, progression and resistance to antineo-
plastic drugs [8]. According to this hypothesis, CSC originate from the transformation of nor-
mal stem cells. Indeed, due to their longevity, stem cells accumulate multiple mutations that
are necessary for carcinogenesis. Supporting this hypothesis, normal stem cells and CSC share
several important properties, including: (a) self-renewal, (b) differentiation, (c) active telome-
rase expression, (d) activation of anti-apoptotic pathways, (e) increased membrane transporter
activity and (f) ability to migrate and metastasize [9]. Furthermore, cancers usually display ex-
tensive phenotypical, functional and molecular heterogeneity that may easily be explained by
the CSC theory [10–12]. Two models have been proposed to elucidate the assorted characteris-
tics of cancer cells within a tumor: 1) the clonal evolution model, and 2) the CSC model. While
the former postulates that all cells within a cancer have the potential to give rise to new tumors,
the latter suggests that only cancer cells with stem-like features can sustain tumor initiation
and progression [13–16]. Experimental evidence in a variety of tumors strongly supports the
CSC hypothesis. The importance of CSC in tumor initiation has been firmly established in leu-
kemia and recently reported in a variety of solid tumors such as breast, colon, brain, prostate,
ovary, lung cancer and melanoma [17–24]. Our group has previously identified and character-
ized a CD133+ tumor cell subpopulation endowed with self-renewal and multi-lineage differ-
entiation capacity just like normal stem cells [25]. This small subpopulation of CSC retains
tumorigenic capacity when transplanted into immune-deficient mice [25,26]. The resulting xe-
nografts are histologically and molecularly similar to the parental tumor from which they origi-
nated [27]. This intriguing property makes CSC a good model for the study of the biology and
sensitivity of tumors of individual patients to antineoplastic agents.
CSC display high expression levels of ATP-binding cassette (ABC) transporters, anti-apo-
ptotic factors, and an active DNA-repair capacity that make them particularly resistant to
drugs and toxins [28–30]. In addition, the apparent tumor debulk obtained with chemotherapy
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contributes to the CSC pool enrichment, thus increasing the risk of developing more resistant
phenotypes [31]. This collective evidence suggests that the common inefficacy of conventional
therapies on the stem cell population might partially explain cancer resistance to available
treatments. Consequently, knowing the spectrum of sensitivity of the CSC subpopulation of
the individual tumor and targeting selectively this subpopulation could provide significant im-
provement of treatment outcomes.
Considering the current lack of specific agents targeting the CSC and the previously re-
ported observations, we conducted a prospective non-randomized study (STELLA trial, Clini-
calTrials.gov: NCT01483001) to evaluate whether isolating and testing CSC against a broad
spectrum of antineoplastic agents is feasible in the clinical setting. Moreover, the study sought
to determine if such an approach could potentially identify drugs with in vitro activity against
the CSC derived from the individual patient, thus providing new personalized therapeutic op-
tions. The study showed that testing of CSC chemosensitivity is feasible in the clinical setting,
although a more efficient in vitromethod is needed.
Methods
Eligibility, recruitment and follow up
The protocol for this trial and supporting TREND checklist are available as supporting infor-
mation; see S1 Protocol and S1 TREND Checklist.
The STELLA study was a prospective, non-randomized, open-label, clinical trial evaluating
the feasibility of the intervention of CSC isolation and chemosensitivity assay in clinic (S1 Pro-
tocol). The study was approved by the “Ethics Review Board for Investigation of Drugs” of the
Civil Hospital of Livorno. Written informed consent was obtained from each patient before en-
rollment. Patients who were followed or referred to the Medical Oncology Department of the
Hospital of Livorno and who met the eligibility criteria were enrolled in the trial. Eligible pa-
tients had confirmed cytological or histological diagnosis of metastatic lung, breast or colorec-
tal cancer; pre-treated with standard therapies and without additional standard therapeutic
options; with a performance status of 100% according to the Karnofsky score; adequate hema-
tological, renal and liver functions. Main ineligibility criteria included the inability to obtain
fresh tumor tissue or neoplastic effusion suitable for CSC extraction and comorbidity potential-
ly interfering with the study. Clinical characteristics of patients as well as molecular features of
tumors (when available) were collected and registered in an electronic database in the Depart-
ment of Medical Oncology of the Civil Hospital of Livorno. Two patients were initially diag-
nosed with a CRC and included in the study, but a pathology revision showed a different
histology (pancreatic cancer and small intestine adenocarcinoma), thus representing a devia-
tion from the study protocol.
The primary objective of the study was to evaluate the feasibility of a sensitivity assay on
CSC in a clinical setting, taking into consideration the percentage of patients for whom it was
possible to perform the assay and the period of time to obtain the sensitivity results. Secondary
end-points were the identification of LC, CRC and BC stem cells and the evaluation of their in
vitro sensitivity to anti-tumor agents. The latter was expressed as mortality rate, i.e. the per-
centage of dead cells after the chemosensitivity assay.
Patients were enrolled over a two months period of time (December 6th, 2011–January 31st,
2012), and were followed up till death or patient’s refusal (December 2011–December 2013) at
regular intervals according to clinical need and opinion of the clinician. Telephone interviews
were performed in case the patient was unable to attend outpatient visits.
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Tissue Collection, Isolation, and Culture of Cancer Cells
Neoplastic effusion (if present) or tumor tissue from primary cancer or from the most accessible
metastatic site was obtained from all eligible patients after informed consent signature in the
Civil Hospital of Livorno. Fresh samples were shipped overnight at room temperature to the Cel-
lular and Molecular Pathophysiology Laboratory of the University of Palermo, Italy. Tumor
specimens were intensively washed in PBS solution and incubated overnight in Dulbecco’s modi-
fied Eagle medium (DMEM, GIBCO) supplemented with penicillin (500 U/ml, GIBCO), strepto-
mycin (500 μg/ml, GIBCO) and amphotericin B (1.25 μg/ml, GIBCO) to avoid microbial
contamination. Tumor samples were enzymatically digested with collagenase and hyaluronidase
and mechanically shaken for 1 hour at 37°C. Alternatively, neoplastic effusions were separated
by centrifugation (1200 rpm, 10 min, 4°C). Collected cells were cultured in stem cell serum free
medium supplemented with epidermal growth factor (EGF, 20 ng/mL, Sigma-Aldrich) and basic
fibroblast growth factor (bFGF, 10 ng/mL, Sigma-Aldrich) and plated in ultra-low attachment
plate (Corning) as previously described [25]. These conditions favour growth of highly tumori-
genic stem-like cells, while negatively selecting for less tumorigenic differentiated tumor cells, as
previously showed by Eramo et al [24]. Surviving immature tumor cells slowly proliferate and
form cell spheres. Sphere-derived cells were expanded by mechanical and/or enzymatic dissocia-
tion and re-plated in complete fresh stem cell medium. Cell cultures were maintained at 37°C in
a 5% CO2 humidified incubator.
The study protocol included in vivo experiments that have never been performed because
all available cells were used for the chemosensitivity tests in the effort of testing as many drugs
as possible and thus identifying a potential treatment for the patient.
Immunofluorescence characterization of spheres
Sphere-derived cells were proven to be CSC by immunofluorescence characterization for stem-
ness membrane markers. Briefly, tumor spheres were mechanically and enzymatically dissoci-
ated to obtain single cells. Cells were fixed and permeablized as previously reported [25].
Cytospun cells were washed in PBS and exposed overnight at 4°C to antibodies against CD133
(AC133, mouse IgG1, Miltenyi), CD166 (mouse IgG1, R&D Systems), OCT3/4 (sc-5279,
mouse IgG2b, Santa Cruz), ALDH-1 (mouse IgG1, BD Bioscience), CD90 (mouse IgG1k, BD
Bioscience), or isotype-matched controls. Afterwards, cells were labelled with fluorescein iso-
thiocyanate (FITC) conjugated mouse antibodies (Invitrogen) and nuclei were counterstained
using Toto-3 iodide. The fluorescent staining was evaluated with a confocal microscope.
In Vitro Sensitivity Assay
After mechanical and enzymatic dissociation, tumor cells were stained with trypan blue and
counted with a haemocytometer. Tumor cells (2X104 per well) were exposed to several anti-
tumor drugs in order to evaluate their sensitivity to the therapeutic compounds. Table 1 indi-
cates the drugs or combinations used. Clinicians empirically chose the drugs to test on the
basis of the previous treatment regimens and the basic molecular aberration of the individual
patient. The in vitro sensitivity assay was performed simultaneously in two 96-well ultra-low
attachment plates (Corning). The treatment time was determined based on drugs half-life and
continued up to 96 hours. Each regimen was evaluated in triplicate.
Cell viability was evaluated with orange acridine/ethidium bromide (AO/EB) staining, as
previously described [34]. The cell suspension was incubated in AO/EB solution in 1:1 ratio re-
spectively and gently mixed. This procedure was performed just before quantification with a
confocal microscope. Eight μl of cell suspension were placed onto a microscopic slide and cov-
ered with a glass coverslip. A confocal microscope was used to examine the sample and
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quantify cell death [34]. The results of the sensitivity assay were communicated to clinicians in
order to select, when possible, a therapy regimen optimized for the individual patient.
Statistical Analysis
Sample size was computed with the software IBM SPSS Sample Power 3.0 on the basis of the
percentage of patients for whom it was possible to perform the assay. Using the test for propor-
tion (two sided test), under the assumption of a percentage of 33% (versus standard procedure
of 5%), a sample size of 18 patients was required, with a power of 90% and a significance level
of 0.05. Descriptive statistics (frequency, percentage, median and inter-quartile range) were
used to analyse data where appropriate. Results of the in vitro procedure (type of samples col-
lected, CSC isolation failure rate) were analysed considering the total number of samples. The
other results (sensitivity assay success rate, time for result and number of drugs tested) were
analysed considering single patient data of the “intention to treat” population.
Results
Patients characteristics
From December 6th 2011 to January 31st 2012, a total of 23 patients were identified at the Med-
ical Oncology Department of Livorno and enrolled in the study (Fig 1). All screened patients
were eligible and started the procedure for CSC isolation. All patients were included in the
Table 1. Drugs and combinations tested in vitro.
Chemotherapeutic agent Target agent
1. Docetaxel 24. Afatinib
2. Temozolomide 25. Cetuximab
3. Topotecan 26. Crizotinib
27. Erlotinib
4. Epirubicin + paclitaxel 28. Nilotinib
5. Carboplatin + etoposide 29. Sunitinib
6. Carboplatin + pemetrexed 30. Sorafenib
7. Carboplatin + vinorelbine 31. Trastuzumab
8. Carboplatin + vinorelbine + cetuximab
9. Cisplatin + docetaxel 32. Afatinib + cetuximab
10. Cisplatin + etoposide 33. Crizotinib + Pemetrexed
11. Cisplatin + pemetrexed 34. Crizotinib + cetuximab
12. Cyclophosphamide + adriamycin + etoposide 35. Crizotinib + everolimus
13. Epirubicin + etoposide 36. Crizotinib + etoposide
14. Epirubicin + ifosfamide 37. Erlotinib + cetuximab
15. Gemcitabine + trastuzumab 38. Erlotinib + crizotinib + cetuximab
16. Oxaliplatin + gemcitabine 39. Erlotinib + everolimus
17. Oxaliplatin + paclitaxel 40. Erlotinib + crizotinib
18. Paclitaxel + trastuzumab 41. Erlotinib + trastuzumab
19. Pemetrexed + topotecan 42. Everolimus + paclitaxel
20. Pemetrexed + cetuximab 43. Nilotinib + erlotinib
21. Vinorelbine + trastuzumab 44. Nilotinib + crizotinib
22. 5-ﬂuorouracyl + oxaliplatin 45 Sorafenib + paclitaxel
23. 5-ﬂuorouracyl + irinotecan 46. Sunitinib + paclitaxel
47. Sunitinib + erlotinib
doi:10.1371/journal.pone.0125037.t001
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following analyses. Table 2 summarizes the clinical characteristics of individual patients. Medi-
an age was 66 years (interquartile range, IQR: 51–72) and the majority of subjects were male
(n = 15, 65%) and had lung cancer (n = 18, 78%). No BC patient was enrolled. Bio-molecular
characterization was not available in 5 cases. Among lung cancer patients, EGFRmutations
were detected in 4 cases, ALK translocation in 1 case and KRASmutation in another case. Two
of the three CRC patients harboured a KRASmutation. Patients received a median of 3 previ-
ous therapy lines (IQR: 1–3). All patients completed the follow-up, except for one patient that
is still alive. No patient was lost to follow-up.
Cancer stem cells isolation and sensitivity assay
Tumor biopsy or neoplastic effusion collection procedure was repeated no more than one time
per patient, except in one case. There were no complications resulting from the tumor tissue/ef-
fusion collection procedure. Isolation of CSC was performed using pleural/peritoneal/pericar-
dial effusion in 13 cases (54%), tumor tissue from lung metastases in 2 cases (8%), liver
metastases in 6 (25%) and lymph node metastases in 3 (13%). CSC were successfully isolated in
15 out of the 24 tumor samples collected (63%). Material was not adequate in 8 cases and one
specimen deteriorated during transportation. The failure rate was higher with tumor biopsies
(5 failed cases out of 11, failure rate: 45%) than with malignant effusions (3 failed cases out of
13, failure rate: 23%). In particular, the lowest yield was obtained with lymph node metastases
Fig 1. Flow chart of the study.
doi:10.1371/journal.pone.0125037.g001
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(2 failed cases out of 3, failure rate: 67%). According to the primary site of cancer, failure rate
was 30% for lung cancer and 80% for gastrointestinal tumors.
Freshly isolated lung tumor cells had stem-like phenotype confirmed by the concomitant
expression of the most common stemness markers, including CD133, CD166, OCT3/4,
ALDH-1 and CD90 (Fig 2) [32,33]. The concomitant high expression of these markers strongly
supports the fact that the isolated cells were CSC. Table 3 shows the pattern of expression of
the markers in the cases in which a sensitivity assay was performed. No immuno-fluorescent
study was performed on gastro-intestinal samples for limited number of isolated cells and in-
sufficient in vitro growth.
Among the 15 cases in which CSC were successfully isolated, in vitro cell growth was ob-
served in 12 and only in 7 cases the number of available cells was sufficient to perform a che-
mosensitivity test. The overall success rate of the whole procedure was 30.4%. The in vitro
response to treatment was evaluated in 96 wells plates in triplicate with AO/EB staining. The
AO/EB staining was used to visualize nuclear changes and apoptotic body formation that are
characteristic of apoptosis. Whereas AO is a vital dye and stains both live and dead cells, EB
stains only cells that lost membrane integrity. Therefore, viable cells appeared uniformly green
and dead cells incorporated EB and, consequently, were stained in orange (Fig 3). Response to
treatment, observed in the first plate labelled with AO/EB, was homogeneous in all three wells.
Table 2. Individual patients characteristics.
Patient
ID
Age Sex Primary
Cancer
Histology Molecular
aberration
Previous treatment
lines
Smoke
habit
Number of tissue/effusions
collections
NP001 72 F LC SCLC No 1 PS 1
PM002 49 M CRC ADC KRAS mut 3 NV 1
SN003 69 F LC ADC No 3 NV 1
LG004 54 M LC SqC No 2 PS 1
ZL005 45 F LC ADC EGFR mut 3 NS 2
GD006 42 M LC ADC EGFR mut 7 PS 1
RG007 71 M LC ADC No 4 CS 1
TR008 70 F LC ADC No 4 NS 1
CM009 48 F LC ADC ALK transl 1 NS 1
GA010 66 M LC NAS No 0 PS 1
CN011 56 M CRC ADC KRAS mut 4 PS 1
BU012 80 M LC ADC No 1 NS 1
BG013 71 M GI ADC NE 0 PS 1
RR014 73 M GI ADC NE 1 PS 1
CM015 74 M LC ADC EGFR mut 2 PS 1
LC016 56 M LC ADC No 2 PS 1
RE017 73 F CRC ADC NE 1 NS 1
SL018 50 F LC ADC No 3 NS 1
PD019 52 M LC ADC KRAS mut 0 PS 1
CV020 49 M LC SqC NE 2 PS 1
ME021 85 F LC ADC No 1 NS 1
CR022 55 M LC SqC NE 6 PS 1
SF023 67 F LC ADC EGFR mut 3 NS 1
Abbreviations: F, female; M, male; LC, lung cancer; CRC, colorectal cancer; GI; other gastrointestinal cancer; SCLC, small cell lung cancer; ADC,
adenocarcinoma; SqC, squamous cell carcinoma; PS, previous smoker; NV, never smoker; CR, current smoker; NE, not evaluated.
doi:10.1371/journal.pone.0125037.t002
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Viable cells of the second plate were kept in culture for observation and no morphologic or
phenotypical change was detected.
All patients whose tumors were successfully tested in vitro had LC, including 5 lung adeno-
carcinomas, 1 undifferentiated non-small cell lung cancer and 1 small cell lung cancer. The me-
dian time between sample collection and sensitivity assay results was 51 days (IQR: 47–54).
Table 1 indicates the drugs or combinations used for the in vitro sensitivity assay and more de-
tailed information about the single tests can be found in Table 3. The median number of drugs/
combinations that were tested was 15 (IQR: 5–22). The in vitro CSC mortality rate ranged
from 0 to 80%, but only in one case the mortality rate was>50% (Table 3).
Patients treatment
The study did not contemplate the treatment of patients and its endpoints did not include
whether the in vitro results correlate with the clinical response. However no valid therapeutic
option was available for these patients and, when possible, we offered them a treatment with
one of the tested drugs. The chosen regimen was always the one with the highest in vitromor-
tality rate. As there is no recognized cut-off value of the in vitro result defining clinical sensitivi-
ty/resistance, it cannot be ruled out that regimens with low in vitromortality may produce
clinical responses and, therefore, the chosen regimen could have had a low mortality rate. As
shown in Table 3, among the 7 subjects for whom a sensitivity assay was available, only 3 re-
ceived a treatment based on the test results. The highest mortality rate observed in vitro was
10% in 2 of these patients and the disease progressed soon after the start of treatment. The first
patient was a never smoker woman with a metastatic lung adenocarcinoma with no molecular
Fig 2. Phenotypical characterization of immature tumor cells isolated from tumor samples with
immunofluorescence assay. The following panel of images refers to the characterization of cells isolated
from the sample of a patient enrolled in the study. Green labelling is typical of positive cells. All markers of
stemness (CD133, CD166, Oct 3/4, ALDH1, CD90) are positive in this CSC sample.
doi:10.1371/journal.pone.0125037.g002
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driver aberration. She received a combination of oxaliplatin and paclitaxel, but the disease pro-
gressed after only two cycles. The second patient was a former smoker man with KRASmutat-
ed advanced adenocarcinoma of the lung. He received a combination of carboplatin and
pemetrexed and his disease progressed soon after. On the other hand, in a young man with a
metastatic EGFRmutated adenocarcinoma of the lung the in vitro assay showed a cell mortality
of 40% for the combination of oxaliplatin and paclitaxel. The patient received 5 cycles of the
above-mentioned chemotherapeutic drugs, achieving a stabilization of disease. Despite the
beneficial effect, considering that the patient had already received 7 lines of treatment, the clini-
cian decided to stop treatment for increased risk of toxicity. The other 4 patients for whom a
sensitivity test was performed did not receive the treatment because they passed away before
results became available. Overall, these anecdotal findings seem to indicate that higher in vitro
sensitivity could translate into better clinical outcome.
Discussion
Accumulating evidence supports the existence of CSCs in human tumors. These cells possess
the capacity to self-renew and differentiate into mature tumor cells. They seem to drive tumor
initiation, progression, and metastasis. Given their high resistance to anticancer drugs, they are
believed to substantially contribute to relapse after chemotherapy and represent an attractive
therapeutic target to potentially achieve long lasting therapeutic responses. Therefore, the rec-
ognition of the most active drugs on the CSC subpopulation has the potential to identify the
best treatment choice for the individual patient or new treatment options for patients progress-
ing on standard therapies.
Previous studies have already described the isolation procedure of CSC. The STELLA study
is the first prospective study that evaluates the applicability of this procedure in a clinical set-
ting with the aim of testing the in vitro sensitivity of CSC and potentially identifying new thera-
peutic options for the patient. Considering that feasibility was the primary end-point of the
study, a limited number of individuals was enrolled, the vast majority with a diagnosis of LC,
the most frequent disease referred to our Institution. The study showed that the procedure was
feasible in 65% of cases, leading to a chemo-sensitivity result in one third of patients in a medi-
an time of 51 days. Overall, this preliminary experience gave us very relevant information.
First of all, site of tumor sample collection was critical for the success of the isolation proce-
dure since neoplastic effusions were the most proficient for such purpose. This is also a relevant
Fig 3. Evaluation of cell mortality with acridine orange/ethidium bromide (AO/EB) staining after exposition to chemotherapeutic agents. AO is a
vital dye and stains both live and dead cells. EB penetrates into cells with disrupted cytoplasmic membrane, staining only dead cells. Therefore, viable cells
appear uniformly green and dead cells are labelled in orange. a) Low sensitivity (cell mortality 5%). b) Average sensitivity (cell mortality 40%). c) High
sensitivity (cell mortality 80%).
doi:10.1371/journal.pone.0125037.g003
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aspect for clinical practice since effusion collection is relatively easy and often required for
symptom management, it has low risk and it is generally well accepted by patients. In our opin-
ion the sample type, whether it was fresh biopsy tissue or neoplastic effusion, was the factor
that mainly impacted on the low percentage of patients benefitting from the test. Other factors,
such as the type of culture medium, may have had a minor impact.
The median time between sample collection and sensitivity assay results was 51 days. This
is a relatively long period of time for metastatic cancer patients, explaining why less than 50%
of subjects for whom the sensitivity test was available received a therapy based on its results.
Whether this lapse of time is sufficient to further alter the tumor cell biology and their sensi-
tivity to drugs is not known and currently there is no scientific evidence of this. In order to
shorten this time frame, based on the STELLA experience, an ongoing clinical study
(LUCAS) is using a different assay (Tecan Infinite F500 after Cell Titer-Glo Luminescent Cell
Viability Assay; Promega). This method determines the number of viable cells based on
quantification of a luminescent signal that is proportional to the amount of ATP; it requires a
smaller number of cells and delivers actionable results in only 7 days from the biopsy. This
might help achieve results in a shorter period of time and test more drugs for patients with
slow in vitro growth of CSC. Moreover, it delivers quantitative results, eliminating the inferi-
or precision of the previous semi-quantitative method. This new approach could also im-
prove the percentage of patients in which the chemosensitivity test can be successfully
performed. In fact, in the STELLA study the sensitivity assay was performed in only 7 cases
mainly for the poor in vitro cell growth.
In our study CSC showed high resistance to currently available drugs, including standard
chemotherapy agents and targeted therapies, with only one case showing a mortality rate above
50%. This is not unexpected considering the high resistance of CSC to commonly used antitu-
mor agents, highlighting the urgent need for more effective drugs specifically targeting this
cell population.
In conclusion, the approach used for the STELLA trial allowed CSC isolation in a consistent
proportion of patients. The low percentage of cases completing the full procedure of chemosen-
sitivity assay and the long median time for obtaining the full results highlights the need for a
more efficient procedure. In such perspective, the currently ongoing LUCAS study will clarify
the potential clinical implications of therapies targeted on CSCs.
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